中国肿瘤生物治疗杂志2012，Vol.19Issue(5)：535-538,4.DOI:10.3872/j.issn.1007-385X.2012.05.014
利妥昔单抗联合CHOP化疗上调钙网蛋白表达提高对NHL的疗效
Up-regulation of calreticulin expression improves the efficacy of rituximab combined CHOP treatment for B-cell non-Hodgkin' s lymphoma
岑海燕 1施文瑜 2徐梦麒2
作者信息
- 1. 南通大学附属医院分院血液科,江苏南通226001
- 2. 南通大学附属医院血液科,江苏南通226001
- 折叠
摘要
Abstract
Objective;To evaluate the clinical efficacy of rituximab (R) combined CHOP ( R-CHOP) treatment on B-cell non-Hodgkin's lymphoma (NHL) and its influence on the expression of calreticulin (CRT). Methods; Totally 48 patients (From Jul. 2008 to Feb. 2011 in Affiliated Hospital of Nantong University) with previously untreated B-cell lymphoma were divided into R-CHOP group (25 cases) and CHOP group (23 cases). R-CHOP group was treated with R-CHOP chemotherapy and CHOP group was treated with CHOP chemotherapy. After 6 treatment courses, the clinical efficacy, adverse effect and the expression of CRT on CD20+ B cells were compared between these two groups. Results: The complete remission rate was 80.0% and the total effective rate was 92.0% in the R-CHOP group. The complete remission rate was 56. 5% and the total effective rate was 69. 6% in the CHOP group. There was a significant difference in the complete remission rate and the total effective rate between the two groups (P <0. 05 ) . There was no significant difference in adverse events between the two groups (P > 0. 05). The expression of CRT on CD20+ B cells in the R-CHOP group was higher than the CHOP group ( [255.00 ±5.57] vs [216. 00 ±3. 61 ] , P<0.05). Rituximab can improve the clinical effciency of CHOP in the treatment of B-cell NHL, which may be related with the expression of CRT induced by combined treatment.关键词
B细胞非霍奇金淋巴瘤/利妥昔单抗/CHOP化疗/钙网蛋白Key words
B-cell non-Hodgkin's lymphoma/rituximab/CHOP chemotherapy/calreticulin分类
医药卫生引用本文复制引用
岑海燕,施文瑜,徐梦麒..利妥昔单抗联合CHOP化疗上调钙网蛋白表达提高对NHL的疗效[J].中国肿瘤生物治疗杂志,2012,19(5):535-538,4.
